Financial health
- The company holds more cash ($164M) than total debt ($53M).
- Operating income covered interest expense -15.6× in the latest year.
NUVB Financials Nuvation Bio Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $63M | -$205M | 0.0% | -338.7% | -66.9% | -34.4% | — | $53M | $164M |
| 2024 | $8M | -$568M | 10.1% | -7527.3% | -122.5% | -105.1% | — | — | $36M |
| 2023 | $0 | -$76M | — | — | -12.5% | -12.2% | — | — | $43M |
| 2022 | — | -$104M | — | — | -15.9% | -15.5% | — | — | $101M |
| 2021 | — | -$87M | — | — | -11.6% | -11.2% | — | — | $132M |
| 2020 | — | -$42M | — | — | -19.4% | -18.8% | — | — | $30M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Mar '26 | $83M | $5M | 0.0% | 4.7% | 1.7% | 0.9% | — | $53M | $125M |
| Dec '25 | $42M | -$37M | 0.0% | -81.3% | -12.0% | -6.2% | — | $53M | $164M |
| Sep '25 | $13M | -$56M | 74.5% | -430.1% | -17.1% | -9.3% | — | $53M | $99M |
| Jun '25 | $5M | -$59M | 46.7% | -1315.7% | -15.8% | -9.1% | — | $53M | $248M |
| Mar '25 | $3M | -$53M | 32.1% | -1913.2% | -12.7% | -10.8% | — | — | $48M |
| Dec '24 | $6M | -$49M | 26.2% | -944.5% | -10.7% | -9.1% | — | — | $36M |
| Sep '24 | $727000 | -$41M | -108.4% | -6616.4% | -8.2% | -7.2% | — | — | $30M |
| Jun '24 | $1M | -$462M | 6.1% | -32779.4% | -179.8% | -77.8% | — | — | $34M |
| Mar '24 | $0 | -$15M | — | — | -2.5% | -2.4% | — | — | $35M |
| Dec '23 | $0 | -$14M | — | — | -2.3% | -2.2% | — | — | $43M |
| Sep '23 | $0 | -$20M | — | — | -3.2% | -3.1% | — | — | $24M |
| Jun '23 | $0 | -$21M | — | — | -3.3% | -3.2% | — | — | $50M |
| Mar '23 | — | -$22M | — | — | -3.4% | -3.3% | — | — | $30M |
| Dec '22 | — | -$21M | — | — | -3.2% | -3.1% | — | — | $101M |
| Sep '22 | — | -$27M | — | — | -4.1% | -4.0% | — | — | $139M |
| Jun '22 | — | -$35M | — | — | -5.0% | -4.8% | — | — | $102M |
| Mar '22 | — | -$21M | — | — | -2.9% | -2.8% | — | — | $106M |
| Dec '21 | — | -$25M | — | — | -3.4% | -3.2% | — | — | $132M |
| Sep '21 | — | -$22M | — | — | -2.9% | -2.8% | — | — | $345M |
| Jun '21 | — | -$19M | — | — | -2.5% | -2.4% | — | — | $450M |
Valuation over time
How the market has priced NUVB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 118.2× (Dec '24) to 25.6× (Nov '26).
P/S
Frequently asked questions
Is NUVB growing its revenue and profit?
See the revenue and net-income charts above for Nuvation Bio Inc.'s multi-year trend.
How much debt does NUVB have?
As of FY2025, Nuvation Bio Inc. reported $53M of total debt against $164M of cash; operating income covered interest expense -15.6×.
What is NUVB's profit margin?
In FY2025, gross margin was —, operating margin -338.7%, and net margin -325.3%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.